Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 56.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,266 shares of the company’s stock after purchasing an additional 56,607 shares during the quarter. Victory Capital Management Inc. owned about 0.27% of Apogee Therapeutics worth $6,149,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. lifted its holdings in Apogee Therapeutics by 9.3% during the 4th quarter. Franklin Resources Inc. now owns 1,089,780 shares of the company’s stock worth $30,448,000 after buying an additional 92,423 shares in the last quarter. Braidwell LP raised its stake in shares of Apogee Therapeutics by 38.7% in the fourth quarter. Braidwell LP now owns 681,101 shares of the company’s stock valued at $19,030,000 after acquiring an additional 189,988 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after purchasing an additional 705,795 shares during the period. Jennison Associates LLC grew its stake in Apogee Therapeutics by 192.0% during the 1st quarter. Jennison Associates LLC now owns 302,892 shares of the company’s stock worth $20,127,000 after purchasing an additional 199,148 shares in the last quarter. Finally, Blackstone Inc. increased its holdings in Apogee Therapeutics by 17.6% during the 4th quarter. Blackstone Inc. now owns 351,810 shares of the company’s stock worth $9,830,000 after purchasing an additional 52,688 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Insider Activity

In related news, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares in the company, valued at $11,084,216.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the sale, the insider now directly owns 294,793 shares in the company, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,995 shares of company stock worth $5,218,774. 36.10% of the stock is currently owned by corporate insiders.

Apogee Therapeutics Price Performance

APGE stock opened at $51.38 on Monday. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29. The firm has a market capitalization of $2.31 billion, a P/E ratio of -9.79 and a beta of 2.74. The business’s 50-day moving average is $46.97 and its two-hundred day moving average is $49.70.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60). On average, analysts expect that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.